VSTM
(NASDAQ)
2.59
+0.0906  (+3.50%)
Volume (24h): 1.67M Day Range: 2.37 - 2.60
Market Cap: 410.79M 52W Range: 0.8300 - 3.49
Mar-30-20 02:37PM Earnings Estimates Moving Higher for Verastem (VSTM): Time to Buy?Zacks
Mar-19-20 03:30PM Has Verastem (VSTM) Outpaced Other Medical Stocks This Year?Zacks
Mar-18-20 11:01AM Verastem Sees Hammer Chart Pattern: Time to Buy?Zacks
Mar-11-20 08:05PM Verastem Oncology Reports Fourth Quarter and Full-Year 2019 Financial ResultsBusiness Wire
Mar-10-20 01:28PM Verastem, Inc. (VSTM) Shares March Higher, Can It Continue?Zacks
Feb-28-20 11:05AM Verastem Oncology Announces New Strategic Direction to Advance Its Clinical Development ProgramsBusiness Wire
11:00AM Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences InvestorsBusiness Wire
Feb-05-20 04:52PM Steven Cohen Renews His Interest in VerastemGuruFocus.com
Jan-29-20 12:06PM Verastem Oncology Announces Dosing of First Patient in CSPC’s Chinese Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Follicular LymphomaBusiness Wire
Jan-21-20 04:14PM Those Who Purchased Verastem (NASDAQ:VSTM) Shares Five Years Ago Have A 74% Loss To Show For ItSimply Wall St.
Jan-09-20 02:00PM Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock UpZacks
Jan-08-20 01:12PM The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study ResultsBenzinga
12:00PM Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766Business Wire
Jan-06-20 12:00PM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Dec-18-19 12:03AM Do Hedge Funds Love Verastem Inc (VSTM)?Insider Monkey
Dec-11-19 01:46PM Implied Volatility Surging for Verastem (VSTM) Stock OptionsZacks
Dec-07-19 02:00PM Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual MeetingBusiness Wire
Nov-25-19 01:57PM Implied Volatility Surging for Verastem (VSTM) Stock OptionsZacks
12:00PM Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)Business Wire
Nov-16-19 04:16AM Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMTThomson Reuters StreetEvents
Nov-14-19 01:42PM Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMTThomson Reuters StreetEvents
Nov-13-19 12:00PM Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care AwardBusiness Wire
Nov-12-19 01:12PM Verastem Oncology Announces Private Exchange of Approximately $114.3 Million of its 5.00% Convertible Senior Notes due 2048 for 5.00% Convertible Senior Second Lien Notes Due 2048Business Wire
Nov-06-19 02:15PM Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual MeetingBusiness Wire
Nov-02-19 10:28PM Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMTThomson Reuters StreetEvents
05:34PM Edited Transcript of VSTM earnings conference call or presentation 29-Oct-19 8:30pm GMTThomson Reuters StreetEvents
Oct-30-19 11:01AM The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen EarningsBenzinga
Oct-29-19 11:35PM Verastem (VSTM) Reports Q3 Loss, Misses Revenue EstimatesZacks
08:17PM Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company ProgressBusiness Wire
Oct-23-19 11:00AM Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Lymphoma & Myeloma 2019 International CongressBusiness Wire
Oct-17-19 11:00AM Verastem Oncology to Announce Third Quarter 2019 Financial Results and Corporate Update on October 29, 2019Business Wire
Oct-09-19 03:18PM Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other UpdatesZacks
Oct-08-19 02:02PM Verastem's (VSTM) Copiktra Gets Orphan Drug DesignationZacks
Oct-07-19 11:00AM Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTRA® (Duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaBusiness Wire
Oct-04-19 05:41PM How Many Verastem, Inc. (NASDAQ:VSTM) Shares Did Insiders Buy, In The Last Year?Simply Wall St.
11:00AM Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
Oct-03-19 06:25PM Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell LymphomaBusiness Wire
11:00AM Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid MalignanciesBusiness Wire
Sep-26-19 11:00AM Verastem Oncology to Present at the Cantor 2019 Global Healthcare ConferenceBusiness Wire
Sep-20-19 05:00PM Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lymphocytic LeukemiaBusiness Wire
Sep-03-19 08:05PM Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment ConferenceBusiness Wire
Aug-07-19 12:52AM Edited Transcript of VSTM earnings conference call or presentation 1-Aug-19 8:30pm GMTThomson Reuters StreetEvents
Aug-05-19 05:13PM Verastem Inc (VSTM) Q2 2019 Earnings Call TranscriptMotley Fool
Aug-01-19 11:25PM Verastem (VSTM) Reports Q2 Loss, Tops Revenue EstimatesZacks
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. The company is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and The Leukemia & Lymphoma Society. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)